Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Müller, U.
Right arrow Articles by Stahel, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Müller, U.
Right arrow Articles by Stahel, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:399-402, 1993
© 1993 European Society for Medical Oncology

research-article

Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma

U. Müller and R. A. Stahel

Division of Oncology, Department of Medicine, University Hospital Zürich, Switzerland

Correspondence to: R. A. Stahel, MD, Division of Oncology, University Hospital, 8091 Zurich, Switzerland

BACKGROUND:: The late effects of chemotherapy of aggressive non-Hodgkin's lymphoma on gonadal function are largely unknown.

PATIENTS AND METHODS:: In a retrospective study the gonadal function after chemotherapy with MACOP-B or VACOP-B with or without dose intensification and ABMT in first remission was examined in patients with aggressive non-Hodgkin's lymphoma by patient history and determination of hormonal function. Thirty adult patients of age 40 or less at diagnosis who were alive and free of relapse for at least 1 year after completion of chemotherapy were included in the study.

RESULTS:: With a median time of 28 months (range 11 to 62 months) after completion of therapy, gonadal dysfunction was found in 1 of 7 female and none of 15 male patients, or a total of 5% of patients treated with chemotherapy alone. Of patients receiving dose intensification and ABMT in first remission, gonadal dysfunction was present in 2/6 (33%) treated with cyclophosphamide, BCNU and etoposide in 3/4 treated with cyclophosphamide and TBI.

CONCLUSIONS:: Our data suggest that therapy of aggressive non-Hodgkin's lymphomas with MACOP-B or VACOP-B has little impact on future fertility and that fertility may be preserved in the majority of patients receiving dose-intensification with CBV in first remission.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
E. J. Dann, R. Epelbaum, I. Avivi, M. Ben Shahar, N. Haim, J. M. Rowe, and Z. Blumenfeld
Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma
Hum. Reprod., August 1, 2005; 20(8): 2247 - 2249.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
S. J. Howell and S. M. Shalet
Spermatogenesis After Cancer Treatment: Damage and Recovery
J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 12 - 17.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Andre, N. Mounier, X. Leleu, A. Sonet, P. Brice, M. Henry-Amar, H. Tilly, B. Coiffier, A. Bosly, P. Morel, et al.
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
Blood, February 15, 2004; 103(4): 1222 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
Z. Blumenfeld, I. Avivi, M. Ritter, and J. M. Rowe
Preservation of Fertility and Ovarian Function and Minimizing Chemotherapy-Induced Gonadotoxicity in Young Women
Reproductive Sciences, September 1, 1999; 6(5): 229 - 239.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.